AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), launched AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers. AGCellerate offers guaranteed amounts at fixed timelines and costs and is designed to help accelerate projects through development and into clinical phases. 

The new program offers support to biologics projects using monoclonal antibodies (mAbs), lentiviral vectors, adeno-associated vectors, and Plasmid DNA (pDNA) material. The AGCellerate mAb program is immediately available, and the company plans to release details on the other modalities later this year.

AGCellerate mAb offers 1.0 KG of clinical ready drug substance in 11 months. This delivers the quantity needed, in a fast timeline and at a fixed price to support strategic early phase goals, helping developers reach the clinic as quickly as possible.

AGCellerate for mAbs is supported by AGC Biologics’ Chef-1 platform, an FDA and EMA approved cell line used in four commercial products and 54 molecules at various stages of clinical development.

The AGCellerate program offers a templated approach to help maximize speed and product deliverables. It is backed by AGC Biologics’ quality services committed to producing GMP compliant biopharmaceuticals, and a global supply chain network to help projects start quickly and remain on time.

“There is one overarching goal for our partners – to create something that will positively affect patients and families seeking life changing treatments. That is at the center of everything we strive to do at AGC Biologics,” said JB Agnus, chief business officer, AGC Biologics. “AGCellerate is designed to help achieve these patient-focused milestones by offering reliable, standardized drug production without surprises.”